Showing results (2381-2390 of 2,546) with videos related to
Sort By:
Pageof 255
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2015
Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected InfantsDespina Contopoulos-Ioannidis, Kelsey M Wheeler, Raymund Ramirez, et al.Medrxiv : the Preprint Server for Health Sciences|June 4, 2026
Low birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal vaccine immunogenicity in Ugandan infantsKenneth Musinguzi, Alyssa N Sbarra, Florian Bach, et al.Plos Neglected Tropical Diseases|June 27, 2017
Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countriesIan J Begeman, Joseph Lykins, Ying Zhou, et al.Cancer Research|December 28, 2013
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignanciesDamian J Green, Nural N Orgun, Jon C Jones, et al.The New England Journal of Medicine|October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Single-Fraction Stereotactic Radiosurgery (SRS) Alone Versus Surgical Resection and SRS for Large Brain Metastases: A Multi-institutional AnalysisRoshan S Prabhu, Robert H Press, Kirtesh R Patel, et al.Nature Communications|January 13, 2026
Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenzaMatthew R Ykema, Michael A Davis, Darshan N Kasal, et al.Bioorganic & Medicinal Chemistry Letters|August 7, 2012
Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathwayIan Bruce, Mohammed Akhlaq, Graham C Bloomfield, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS StudyLaurie H Sehn, Andre Goy, Fritz C Offner, et al.Journal of Medicinal Chemistry|August 20, 2015
Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Neil J Press, Roger J Taylor, Joseph D Fullerton, et al.Pageof 255